Summary
Project Summary Corneal diseases pose a significant public health challenge in the United States, often leading to vision impairment and decreased quality of life. Mesenchymal stem cell (MSC) delivery to the cornea after a severe injury has shown promise by accelerating repair and significantly suppressing inflammation. However, a major bottleneck in developing MSC therapy for corneal repair is the lack of effective delivery methods. Moreover, optimizing the dosage and timing of MSC therapy is crucial for achieving therapeutic outcomes while minimizing side effects. MSCs must also survive and
